Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHalma Regulatory News (HLMA)

Share Price Information for Halma (HLMA)

Share Price is delayed by 15 minutes
Get Live Data
4,664.00    -214.00 (-4.39%)
Bid:
4,682.00
Ask:
4,686.00
Spread: 4.00 (0.085%)
Market Cap: £17.62b
HLMA Live PriceLast checked at - London Stock Exchange

Intraday Halma Share Chart

Acquisition

20 Dec 2007 07:00

Halma PLC20 December 2007 Halma p.l.c. ACQUISITION OF RIESTER Expansion of Halma's Health and Analysis Sector Halma, the leading safety, health and sensor technology group, announces it hasacquired PP Medizintechnik GmbH and its subsidiaries Rudolf Riester GmbH & Co KGand Riester Verwaltungs GmbH (collectively 'Riester') from Paragon SecondaryPartners L.P. and G. Glufke for €55 million (£39.3 million) net cash. Riester, based in Jungingen, Germany, is a leading manufacturer of smalldiagnostic medical devices for applications including Ophthalmology, BloodPressure measurement and Ear, Nose and Throat diagnostics. Riester is aninternationally recognised brand and generates over 90% of its revenue outsideof Germany. The current CEO of Riester, Gerhard Glufke, will remain with thebusiness. In the year ended 31 December 2006, Riester's revenues and operating profitswere €19.4 million (£13.9 million) and €5.6 million (£4 million) respectively;the management accounts for the nine months ended 30 September 2007 indicatecontinued growth, with operating profits of €4.6 million (£3.3 million) (note2). The acquisition, which is immediately earnings enhancing in the currentfinancial year, has been funded from Halma's existing cash and debt facilities. There will be a • for • adjustment to the consideration paid, capped at €2million (£1.4 million), based on the level of net tangible assets at 31 December2007, with any adjustment payable by 6 March 2008. Andrew Williams, Halma's Chief Executive, commented: "Riester adds new products and sales channels to our existing Health Opticsbusiness, particularly in the medical doctor and practitioner market segment. Their geographic footprint is highly complementary with a strong presence inSpanish speaking territories. It is an excellent addition to our Health andAnalysis sector where we remain well placed to grow organically and throughfurther acquisitions. We welcome the Riester team to Halma." For further information please contact: Halma p.l.c. +44 (0)1494 721111Andrew Williams, Chief ExecutiveKevin Thompson, Finance Director Hogarth Partnership Limited +44 (0)20 7357 9477Rachel Hirst/Andrew Jacques Notes to editors 1. A copy of this announcement, together with other information about Halma, may be viewed on its website: www.halma.com 2. The operating profit figures are stated before goodwill amortisation, interest and non-recurring management fees. In the year ended 31 December 2006, these three items totalled €3.3 million (£2.4 million). Goodwill amortisation, interest and management charges arose as a result of the non-trading holding company structure implemented upon PP Medizintechnik GmbH's acquisition of the subsidiaries in 2005. 3. Riester's gross assets as at 31 December 2006 were €25.8 million (£18.4 million), including €16.1 million (£11.5 million) of goodwill. 4. This statement is not intended to constitute a profit forecast for the current financial period or any future period. In addition, this statement should not be taken to mean that the earnings per share of Halma will necessarily match or exceed the historic reported earnings per share of Halma. 5. Exchange rate used: £1 : €1.40 6. Forward-looking statements have been made by the Directors in good faith using information available up until the date that they approved this statement. Forward-looking statements should be regarded with caution because of the inherent uncertainties in economic trends and business risks. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th May 20267:15 amRNSExecutive Board changes
13th Apr 20267:00 amRNSAcquisition
12th Mar 20267:00 amRNSTrading Update
13th Jan 20269:18 amRNSDirector/PDMR Shareholding
9th Jan 20261:26 pmRNSDirector/PDMR Shareholding
9th Jan 20267:00 amRNSAcquisition
5th Dec 20257:00 amRNSAcquisition
20th Nov 20257:00 amRNSHalf Year Results
1st Oct 20252:00 pmRNSDirector/PDMR Shareholding
26th Sep 202510:19 amRNSDirector/PDMR Shareholding
25th Sep 20257:00 amRNSTrading Update
26th Aug 20257:00 amRNSAcquisition
24th Jul 20252:15 pmRNSResult of AGM
30th Jun 202511:30 amRNSDirector/PDMR Shareholding
25th Jun 20258:30 amRNSAGM - Revised Form of Proxy
24th Jun 20259:20 amRNSDirector/PDMR Shareholding
20th Jun 20255:15 pmRNSAnnual Financial Report
18th Jun 20254:47 pmRNSDirector/PDMR Shareholding
12th Jun 20257:00 amRNSFull Year Results
16th May 20257:00 amRNSDirectorate Change
28th Mar 20251:10 pmRNSDirector/PDMR Shareholding
21st Mar 20252:00 pmRNSDirectorate Change
13th Mar 20257:00 amRNSTrading Update
28th Feb 20254:29 pmRNSDirector/PDMR Shareholding
14th Jan 20252:05 pmRNSDirector/PDMR Shareholding
8th Jan 20257:00 amRNSAppointment of Chief Financial Officer
28th Nov 202410:04 amRNSDirector/PDMR Shareholding
22nd Nov 20243:30 pmRNSDirector/PDMR Shareholding
22nd Nov 20243:26 pmRNSDirector/PDMR Shareholding
21st Nov 20247:00 amRNSHalf Year Results
18th Nov 20247:00 amRNSAcquisition
6th Nov 20242:34 pmRNSDirector Declaration
2nd Oct 20249:20 amRNSDirector/PDMR Shareholding
26th Sep 20247:00 amRNSTrading Update
24th Sep 20249:45 amRNSDirector/PDMR Shareholding
3rd Sep 20249:15 amRNSPDMR Shareholding
25th Jul 20241:51 pmRNSResult of AGM
24th Jul 20249:15 amRNSDirector/PDMR Shareholding
17th Jul 202412:46 pmRNSDirector Declaration
1st Jul 20249:51 amRNSDirector/PDMR Shareholding
27th Jun 20247:00 amRNSAcquisition
25th Jun 20243:00 pmRNSDirector/PDMR Shareholding
24th Jun 20245:26 pmRNSAnnual Financial Report
13th Jun 20247:00 amRNSFull Year Results
1st May 20247:00 amRNSAcquisition
19th Mar 20243:53 pmRNSDirector/PDMR Shareholding
14th Mar 20247:00 amRNSTrading Update
4th Mar 20247:00 amRNSAcquisition
21st Feb 20244:17 pmRNSDirector/PDMR Shareholding
30th Jan 20247:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.